Finch Therapeutics Group, Inc. (FNCH)

Market Cap	19.51M
Revenue (ttm)	n/a
Net Income (ttm)	-14.17M
Shares Out	1.61M
EPS (ttm)	-8.82
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,968
Open	12.00
Previous Close	12.14
Day's Range	11.55 - 12.28
52-Week Range	0.80 - 14.26
Beta	1.33
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 8, 2024

About Finch Therapeutics Group

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn’s disease; and other microbiome product candidates. The company has collaboratio...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 1
• Stock Exchange: OTCMKTS
• Ticker Symbol: FNCH

Financial Performance

In 2023, Finch Therapeutics Group's revenue was $107,000, a decrease of -87.57% compared to the previous year's $861,000. Losses were -$74.75 million, -34.80% less than in 2022.